Vamil Divan
Stock Analyst at Guggenheim
(4.82)
# 98
Out of 5,113 analysts
246
Total ratings
68.54%
Success rate
21.8%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Buy | $227 → $240 | $224.44 | +6.93% | 19 | Jan 23, 2026 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $115 → $124 | $80.45 | +54.13% | 14 | Jan 16, 2026 | |
| INSM Insmed | Maintains: Buy | $230 → $221 | $162.64 | +35.88% | 8 | Dec 18, 2025 | |
| PFE Pfizer | Maintains: Buy | $33 → $35 | $26.50 | +32.08% | 23 | Nov 24, 2025 | |
| JBIO Jade Biosciences | Maintains: Buy | $14 → $17 | $16.02 | +6.12% | 2 | Nov 18, 2025 | |
| ELDN Eledon Pharmaceuticals | Maintains: Buy | $9 → $8 | $2.20 | +263.64% | 1 | Nov 18, 2025 | |
| SCYX SCYNEXIS | Maintains: Buy | $4 → $3 | $0.80 | +275.00% | 3 | Oct 28, 2025 | |
| ABBV AbbVie | Maintains: Buy | $227 → $242 | $223.93 | +8.07% | 28 | Oct 20, 2025 | |
| SVRA Savara | Maintains: Buy | $8 → $11 | $5.85 | +88.03% | 2 | Sep 9, 2025 | |
| VALN Valneva SE | Maintains: Buy | $14 → $13 | $9.62 | +35.14% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $39 | $27.52 | +41.72% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $2.22 | +216.03% | 2 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $288 | $351.32 | -18.02% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $7.20 | +733.33% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $107.92 | +6.56% | 14 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $30.03 | +56.51% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.98 | +235.57% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $46.75 | +30.48% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $18.28 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $4.10 | +534.15% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.64 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $26.20 | -27.48% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $133.89 | -26.81% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $33.52 | +1.43% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.02 | +231.13% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $188.02 | -73.94% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $1,039.51 | -65.75% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $7.51 | -20.11% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $12.67 | +1,115.47% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $4.94 | +203.64% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $34.73 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $32.53 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $22.08 | -32.07% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $55.56 | +9.79% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $3.42 | +2,911.70% | 3 | Jan 17, 2018 |
Johnson & Johnson
Jan 23, 2026
Maintains: Buy
Price Target: $227 → $240
Current: $224.44
Upside: +6.93%
ANI Pharmaceuticals
Jan 16, 2026
Maintains: Buy
Price Target: $115 → $124
Current: $80.45
Upside: +54.13%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $230 → $221
Current: $162.64
Upside: +35.88%
Pfizer
Nov 24, 2025
Maintains: Buy
Price Target: $33 → $35
Current: $26.50
Upside: +32.08%
Jade Biosciences
Nov 18, 2025
Maintains: Buy
Price Target: $14 → $17
Current: $16.02
Upside: +6.12%
Eledon Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.20
Upside: +263.64%
SCYNEXIS
Oct 28, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.80
Upside: +275.00%
AbbVie
Oct 20, 2025
Maintains: Buy
Price Target: $227 → $242
Current: $223.93
Upside: +8.07%
Savara
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $5.85
Upside: +88.03%
Valneva SE
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $9.62
Upside: +35.14%
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $39
Current: $27.52
Upside: +41.72%
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.22
Upside: +216.03%
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $351.32
Upside: -18.02%
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $7.20
Upside: +733.33%
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $107.92
Upside: +6.56%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $30.03
Upside: +56.51%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $2.98
Upside: +235.57%
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $46.75
Upside: +30.48%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $18.28
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $4.10
Upside: +534.15%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $2.64
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $26.20
Upside: -27.48%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $133.89
Upside: -26.81%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $33.52
Upside: +1.43%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $3.02
Upside: +231.13%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $188.02
Upside: -73.94%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $1,039.51
Upside: -65.75%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $7.51
Upside: -20.11%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $12.67
Upside: +1,115.47%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $4.94
Upside: +203.64%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $34.73
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $32.53
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $22.08
Upside: -32.07%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $55.56
Upside: +9.79%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $3.42
Upside: +2,911.70%